Cogent Biosciences Inc
COGT35.350USD
-0.220-0.62%
Close 01/09, 16:00（ET）Quotes delayed by 15 min
4.94BMarket Cap
LossP/E TTM
More Details of Cogent Biosciences Inc Company
Cogent Biosciences, Inc. is a biotechnology company. The Company is focused on developing precision therapies for genetically defined diseases. The Company’s clinical program, bezuclastinib, is a selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. KIT D816V is responsible for driving systemic mastocytosis, a serious disease caused by unchecked proliferation of mast cells. In addition to bezuclastinib, the Company is developing a portfolio of novel targeted therapies to help patients fighting serious, genetically driven diseases initially targeting mutations in FGFR2, ErbB2 and PI3Kα. SUMMIT is its randomized, global, multicenter, double-blind, placebo-controlled, multi-part Phase II clinical trial for patients with Non-AdvSM. APEX is an open-label, global, multicenter study evaluating the safety, efficacy, pharmacokinetic, and pharmacodynamic profiles of bezuclastinib.
Cogent Biosciences Inc Info
Ticker SymbolCOGT
Company nameCogent Biosciences Inc
IPO dateMar 29, 2018
CEORobbins (Andrew R)
Number of employees205
Security typeOrdinary Share
Fiscal year-endMar 29
Address275 Wyman Street
CityWALTHAM
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code02451
Phone16179455576
Websitehttps://www.cogentbio.com/
Ticker SymbolCOGT
IPO dateMar 29, 2018
CEORobbins (Andrew R)
Company Executives of Cogent Biosciences Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Cole Pinnow
Mr. Cole Pinnow
Chief Commercial Officer
Chief Commercial Officer
215.05K
+169200.00%
Mr. John L. Green
Mr. John L. Green
Chief Financial Officer
Chief Financial Officer
131.83K
+131834.00%
Dr. Karen Jean Ferrante, M.D.
Dr. Karen Jean Ferrante, M.D.
Independent Director
Independent Director
--
--
Dr. Jessica Sachs, M.D.
Dr. Jessica Sachs, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Matthew E. Ros
Mr. Matthew E. Ros
Independent Director
Independent Director
--
--
Ms. Arlene M. Morris
Ms. Arlene M. Morris
Independent Director
Independent Director
--
--
Dr. Chris W. Cain, Ph.D.
Dr. Chris W. Cain, Ph.D.
Independent Director
Independent Director
--
--
Mr. Peter Harwin
Mr. Peter Harwin
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Andrew Robbins
Mr. Andrew Robbins
Chief Executive Officer, President, Director
Chief Executive Officer, President, Director
--
--
Mr. Todd E. Shegog
Mr. Todd E. Shegog
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Cole Pinnow
Mr. Cole Pinnow
Chief Commercial Officer
Chief Commercial Officer
215.05K
+169200.00%
Mr. John L. Green
Mr. John L. Green
Chief Financial Officer
Chief Financial Officer
131.83K
+131834.00%
Dr. Karen Jean Ferrante, M.D.
Dr. Karen Jean Ferrante, M.D.
Independent Director
Independent Director
--
--
Dr. Jessica Sachs, M.D.
Dr. Jessica Sachs, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Matthew E. Ros
Mr. Matthew E. Ros
Independent Director
Independent Director
--
--
Ms. Arlene M. Morris
Ms. Arlene M. Morris
Independent Director
Independent Director
--
--
Revenue Breakdown
FY2021
Relevant data have not been disclosed by the company yet.
By RegionUSD
Name
Revenue
Proportion
United States
0.00
0.00%
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Mon, Nov 17
Updated: Mon, Nov 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Fidelity Management & Research Company LLC
11.79%
BlackRock Institutional Trust Company, N.A.
5.33%
Deerfield Management Company, L.P.
5.16%
Fairmount Funds Management LLC
5.14%
Kynam Capital Management LP
4.50%
Other
68.09%
Shareholders
Shareholders
Proportion
Fidelity Management & Research Company LLC
11.79%
BlackRock Institutional Trust Company, N.A.
5.33%
Deerfield Management Company, L.P.
5.16%
Fairmount Funds Management LLC
5.14%
Kynam Capital Management LP
4.50%
Other
68.09%
Shareholder Types
Shareholders
Proportion
Investment Advisor
36.54%
Hedge Fund
32.47%
Investment Advisor/Hedge Fund
13.94%
Venture Capital
5.54%
Research Firm
2.99%
Individual Investor
0.79%
Family Office
0.60%
Bank and Trust
0.20%
Pension Fund
0.18%
Other
6.74%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
383
160.96M
91.83%
+4.73M
2025Q3
391
160.54M
119.76%
+11.81M
2025Q2
378
137.60M
139.95%
+2.50M
2025Q1
364
134.41M
125.09%
-8.01M
2024Q4
353
122.33M
126.11%
-134.16K
2024Q3
351
122.42M
128.81%
+503.15K
2024Q2
342
121.93M
134.81%
+12.11M
2024Q1
330
109.82M
117.23%
-2.27M
2023Q4
309
92.99M
116.35%
-90.35K
2023Q3
296
94.93M
117.48%
+2.27M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Fidelity Management & Research Company LLC
20.66M
11.79%
+4.72M
+29.60%
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
9.33M
5.33%
+1.57M
+20.24%
Sep 30, 2025
Deerfield Management Company, L.P.
9.05M
5.16%
--
--
Sep 30, 2025
Fairmount Funds Management LLC
9.00M
5.14%
--
--
Nov 13, 2025
Kynam Capital Management LP
7.89M
4.5%
-606.38K
-7.14%
Sep 30, 2025
The Vanguard Group, Inc.
7.73M
4.41%
+1.23M
+18.87%
Sep 30, 2025
Commodore Capital LP
7.25M
4.14%
+3.80M
+110.14%
Sep 30, 2025
TCG Crossover Management, LLC
6.80M
3.88%
-166.21K
-2.39%
Sep 30, 2025
State Street Investment Management (US)
4.78M
2.72%
+1.40M
+41.62%
Sep 30, 2025
VR Adviser, LLC
4.00M
2.28%
-755.41K
-15.89%
Sep 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Tema Oncology ETF
1.85%
Virtus LifeSci Biotech Clinical Trials ETF
1.53%
State Street SPDR S&P Biotech ETF
0.59%
Invesco Dorsey Wright SmallCap Momentum ETF
0.49%
iShares Micro-Cap ETF
0.41%
Direxion Daily S&P Biotech Bull 3X Shares
0.36%
Federated Hermes MDT Small Cap Core ETF
0.29%
Optimize Strategy Index ETF
0.27%
ProShares Ultra Nasdaq Biotechnology
0.22%
Invesco Nasdaq Biotechnology ETF
0.22%
View more
Tema Oncology ETF
Proportion1.85%
Virtus LifeSci Biotech Clinical Trials ETF
Proportion1.53%
State Street SPDR S&P Biotech ETF
Proportion0.59%
Invesco Dorsey Wright SmallCap Momentum ETF
Proportion0.49%
iShares Micro-Cap ETF
Proportion0.41%
Direxion Daily S&P Biotech Bull 3X Shares
Proportion0.36%
Federated Hermes MDT Small Cap Core ETF
Proportion0.29%
Optimize Strategy Index ETF
Proportion0.27%
ProShares Ultra Nasdaq Biotechnology
Proportion0.22%
Invesco Nasdaq Biotechnology ETF
Proportion0.22%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Nov 06, 2020
Merger
4→1
Nov 06, 2020
Merger
4→1
Nov 06, 2020
Merger
4→1
Nov 06, 2020
Merger
4→1
Date
Type
Ratio
Nov 06, 2020
Merger
4→1
Nov 06, 2020
Merger
4→1
Nov 06, 2020
Merger
4→1
Nov 06, 2020
Merger
4→1
FAQs
Who are the top five shareholders of Cogent Biosciences Inc?
The top five shareholders of Cogent Biosciences Inc are:
Fidelity Management & Research Company LLC holds 20.66M shares, accounting for 11.79% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 9.33M shares, accounting for 5.33% of the total shares.
Deerfield Management Company, L.P. holds 9.05M shares, accounting for 5.16% of the total shares.
Fairmount Funds Management LLC holds 9.00M shares, accounting for 5.14% of the total shares.
Kynam Capital Management LP holds 7.89M shares, accounting for 4.50% of the total shares.
Fidelity Management & Research Company LLC holds 20.66M shares, accounting for 11.79% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 9.33M shares, accounting for 5.33% of the total shares.
Deerfield Management Company, L.P. holds 9.05M shares, accounting for 5.16% of the total shares.
Fairmount Funds Management LLC holds 9.00M shares, accounting for 5.14% of the total shares.
Kynam Capital Management LP holds 7.89M shares, accounting for 4.50% of the total shares.
What are the top three shareholder types of Cogent Biosciences Inc?
The top three shareholder types of Cogent Biosciences Inc are:
Fidelity Management & Research Company LLC
BlackRock Institutional Trust Company, N.A.
Deerfield Management Company, L.P.
Fidelity Management & Research Company LLC
BlackRock Institutional Trust Company, N.A.
Deerfield Management Company, L.P.
How many institutions hold shares of Cogent Biosciences Inc (COGT)?
As of 2025Q4, 383 institutions hold shares of Cogent Biosciences Inc, with a combined market value of approximately 160.96M, accounting for 91.83% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -27.94%.
What is the biggest source of revenue for Cogent Biosciences Inc?
In FY2021, the -- business generated the highest revenue for Cogent Biosciences Inc, amounting to -- and accounting for --% of total revenue.
